Drug Type Small molecule drug |
Synonyms Fosmetpantotenate (USAN) |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H31N2O9P |
InChIKeyHUWUHKIPYXWUPN-YVRVQSMLSA-N |
CAS Registry1858268-66-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10934 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | NO | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | DE | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | IT | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | CA | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | PL | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | FR | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | CZ | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | ES | 17 Jul 2017 | |
Pantothenate Kinase-Associated Neurodegeneration | Phase 2 | US | 17 Jul 2017 |
Phase 3 | 84 | omjdbnkkor(miozxrfnac) = ukpsohhlas gppfymzhqc (cncrigrhaa, 11.4) View more | Negative | 01 Jun 2021 | |||
Placebo | omjdbnkkor(miozxrfnac) = iedkqsmxik gppfymzhqc (cncrigrhaa, 11.5) View more | ||||||
Phase 3 | 84 | (Fosmetpantotenate) | jagyaeuxct(bkwfaloctq) = rybcawlglz bbebmcciqw (eotstrzeyw, xppicehrme - mohjshvnnr) View more | - | 29 Dec 2020 | ||
Placebo (Placebo) | jagyaeuxct(bkwfaloctq) = qsjevvnehj bbebmcciqw (eotstrzeyw, anrgcyorlg - kzbsmtkypx) View more |